Tocagen Expands Phase II/III Trial, Begins Enrolling in Canada

Tocagen Inc. expanded its phase II/III clinical trial Toca 5, and is now enrolling patients in Canada. The trial first began enrolling patients in the U.S. in December 2015.

The study compares the combination of Toca 511 (vocimagene amiretrorepvec) and Toca FC (extended-release 5-fluorocytosine) to standard of care in patients with first or second recurrence of glioblastoma or anaplastic astrocytoma who are undergoing resection.